---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053248"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T21:51:18.562225+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# EyePoint's DURAVYU misses Phase 2 NPDR primary endpoint; shows reduced progression at 9 months

## Summary
- Primary endpoint not met: 5% (3mg), 0% (2mg) vs 5% control achieved ≥2-step DRSS improvement at 9 months.
- 86% (3mg) and 80% (2mg) patients stable/improved vs 70% control; 0% (3mg) worsened ≥2-step vs 10% control.
- No drug-related serious adverse events reported; favorable safety profile maintained.
- Company on track for Phase 3 wet AMD trial (LUGANO) in H2 2024 and DME trial (VERONA) data in Q1 2025.

## SEC filing metadata
- accession: 0000950170-24-053248
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024053248/0000950170-24-053248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024053248/eypt-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053248
- JSON: https://secwatch.observer/filing/0000950170-24-053248.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053248.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.